All News

Patients with early-onset Parkinson disease may have been born with disordered brain cells that mishandled dopamine for decades, according to a study released Monday.

Chinese health authorities are testing an HIV drug, lopinavir and ritonavir, as a potential treatment for the new coronavirus; a debate is growing over the efficacy of the sole drug approved to prevent preterm birth; the Trump administration threatens to withhold Califonia’s federal funding due to its abortion coverage requirements.

Following cataract surgery, a submicron formulation of loteprednol etabonate (LE) gel, 0.38% administered three times daily (TID), is safe and effective for treating ocular inflammation with minimal risk of intraocular pressure (IOP) elevation, according to study findings.

Researchers recently discovered a sensitive and specific biomarker that may enable early diagnosis, treatment, and public awareness of spotted fever rickettsial infections, including Mediterranean spotted fever (MSF), according to a study published in the American Journal of Pathology.

Extracting lung function measurements from electronic health record (EHR) data through an automated tool, such as Microsoft SQL Server’s full-text search feature, may be efficient and improve the number of values available, leading to improved phenotyping of patients with COPD, according to study findings.

The authors write that the drug's apparent cardioprotective effects in the angiotensin II stressed mice—the decreased fibrosis, reduced inflammation and oxidative stress—all merit further study.

Researchers compared the cost-effectiveness of ninetedanib to pirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF) and found nintedanib to be more cost-saving than pirfenidone, according to study findings.

The literature review examined randomized controlled trials for craniosacral therapy (CST) in patients with migraine and other conditions that cause pain.

The Institute for Clinical and Economic Review (ICER) published a draft evidence report on crizanlizumab (Adakveo), voxelotor (Oxbryta), and L-glutamine (Endari) for sickle cell disease, as well as a draft scoping document on valoctocogene roxaparvovec, an investigational gene therapy, and emicizumab (Helimbra) for hemophilia.

Shifting towards an anti-inflammatory and suppressive homeostatic immune system may contribute to increased clinical efficacy of siponimod in patients with secondary progressive multiple sclerosis (SPMS), a recent study in JCI Insight reported.

This week, the top managed care stories included a case involving health coverage for birth control reaching the Supreme Court; polls on healthcare anger President Trump; a popular diabetes drug receives a new indication.

Balance training of moderate intensity (BT) may increase anti-inflammatory cytokines and neurotrophic factor levels of patients with Parkinson disease (PD), according to study findings.

A formulation of calcipotriene and betamethasone dipropionate cream met its primary endpoint for treating plaque psoriasis during its phase 3 trial in the European Union, according to an announcement from MC2 Therapeutics.

Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.

A pharmaceutical company executive is sentenced for his role in the opioid crisis; the CDC confirms the second US case of the Chinese coronavirus; the FDA issues accelerated approval of Tazverik for epithelioid sarcoma.

While global public health officials grapple with how to screen international travelers for a spreading coronavirus and the 2019-2020 flu season has claimed the lives of 54 US children so far, hospital groups and physician groups warned this week in court filings about another issue they say is a public health emergency: The Trump administration’s public charge rule, which will defer immigrants, as well as citizens, from seeking healthcare.

Jeffrey D. Dunn, PharmD, MBA, has served as vice president of clinical strategy and programs and industry relations at MagellanRx, a national pharmacy benefit manager (PBM); cofounder, senior vice president, chief clinical officer, and board member of VRx, a regional PBM; and pharmacy director of SelectHealth, part of Intermountain Healthcare. Dunn was instrumental in opening and running the VRx retail pharmacy in downtown Salt Lake City, Utah. He is a board member of Care Pharmacies Cooperative, a chain of 100 retail pharmacies. An editor from The American Journal of Managed Care® recently conducted a question-and-answer session with Dunn regarding the recent Institute for Clinical and Economic Review report on the cost-effectiveness of oral semaglutide.

Minimal residual disease (MRD), a measure of how many cancer cells remain in a patient during or following chemotherapy or stem cell transplant, is a potent indicator of whether or not a patient is likely to relapse; recent research probed the associations between MRD status and certain prognostic risk factors in childhood B-lymphoblastic leukemia after both induction and consolidation.

The US Surgeon General, Jerome M. Adams, MD, MPH, has released the first report since 1990 that focuses solely on smoking cessation in America. Smoking accounts for the deaths of half a million Americans each year and is the leading cause of preventable disease, disability, and death in the country.

Results from an analysis conducted by the Pharmacy Benefit Management Institute (PBMI) show that the use of Jardiance (empagliflozin) among employees with type 2 diabetes and cardiovascular disease can save employers around $737,000 per 10,000 covered lives each year.

A group of 18 health plans announce they will manufacture generic drugs; President Trump hints at cutting Medicare funding; the Chinese government quarantines a city of 11 million in an effort to stop the spread of the coronavirus.

Innovaccer’s survey-based report titled, “The Science of Value-based Care: An Industry View,” details the current state of readiness of healthcare organizations in employing value-based care, while also providing tips on how minor changes in one’s system framework can contribute to clinical excellence and technical efficiency.

Teprotumumab, which was approved this week by the FDA, resulted in a greater frequency of proptosis reduction compared with placebo for patients with active thyroid eye disease, according to study results released Wednesday.

Researchers discuss optimal approaches to treating hypertension in patients with COPD, with a given patient’s underlying lung function and any coexisting conditions highlighted as important factors of drug therapy choice.

Jazz Pharmaceuticals announced today it had redeemed its priority review voucher to submit a New Drug Application to the FDA on January 21, 2020; the company seeks approval for JZP-258, an investigational medication to treat cataplexy and excessive daytime sleepiness in patients 7 years and older with narcolepsy.

Researchers determined that new diagnostic criteria in the International Classification of Headache Disorders, 3rd edition (ICHD-3) are significantly more specific than that included in ICHD-3 beta when it comes to diagnosing migraine with aura and with typical aura, according to a study published in The Journal of Headache and Pain.

https://www.pharmacytimes.org/on-demand/improving-treatment-and-outcomes-in-spinal-muscular-atrophy-patients

https://www.pharmacytimes.org/on-demand/managing-vasoocclusive-crisis-in-sickle-cell-disease-a-look-at-the-clinical-and-economic-burden